As of Jul 21
| -5.21 / -1.00%|
The 20 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 477.50, with a high estimate of 589.00 and a low estimate of 327.00. The median estimate represents a -7.45% decrease from the last price of 515.92.
The current consensus among 24 polled investment analysts is to Hold stock in Regeneron Pharmaceuticals. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.